News
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...
The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.
The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...
The study found Blenrep had no notable effects on progression-free survival, ... good for 59% year-over-year growth. GSK multiple myeloma Blenrep CAR-T Clinical Data Pharma. Connect. The Team; ...
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended ...
FDA Approves GSK’s BLENREP ... The effects were not reversible in male rats but were reversible in female rats. Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results